Saving patients from severe heart failure
The ICOMS FlowMaker® is a novel intracardiac assist device designed to improve the quality of life for severe heart failure patients, aiming for EU market entry by 2026 through clinical trials.
Projectdetails
Introduction
The ICOMS FlowMaker® is the first intracardiac assist device that overcomes all shortcomings of current and under development devices and restores patient's quality of life.
Design and Functionality
Its design perfectly fits all the needs of patients suffering from severe heart failure. Implanted inside the left ventricle and synchronized with the natural heartbeat, it assists the heart to push blood in a physiological way.
Advantages
- The very low electrical consumption allows for wireless functioning.
- With no driveline crossing the skin, the risk of infection is suppressed.
- Without bypass to aorta and thanks to its pulsatile mode, the risk of bleeding is very low.
Market Need
The ICOMS FlowMaker® addresses the market of severe heart failure, where 95% of patients are left without any solution.
Project Aim
The aim of the project is to conduct the clinical trials to enter the EU market in 2026, then the US market, allowing to finally achieve EU sovereignty in severe heart failure treatment.
Financiële details & Tijdlijn
Financiële details
Subsidiebedrag | € 2.500.000 |
Totale projectbegroting | € 9.903.923 |
Tijdlijn
Startdatum | 1-10-2022 |
Einddatum | 31-3-2025 |
Subsidiejaar | 2022 |
Partners & Locaties
Projectpartners
- FINEHEARTpenvoerder
Land(en)
Vergelijkbare projecten binnen EIC Accelerator
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
Transcatheter Ventricular Repair Device for treatment of Heart Failure PatientsCardiac Success aims to develop the V-sling, a transcatheter device to enhance heart function in heart failure patients, through product optimization and pre-clinical testing. | EIC Accelerator | € 2.500.000 | 2022 | Details |
A revolutionary technology platform for providing life-saving treatment for end-stage heart failure patientsreBEAT is an innovative heart support technology that safely assists both sides of the heart, aiming to improve treatment accessibility and cost-effectiveness for end-stage heart failure patients. | EIC Accelerator | € 2.499.999 | 2023 | Details |
Innovative, minimally invasive device to support the natural movement of the heart in heart failure patientsSyntach CS is an innovative implantable device that restores natural heart movement in patients with left ventricular heart failure, enhancing cardiac function through synchronized support. | EIC Accelerator | € 2.500.000 | 2022 | Details |
The first heart failure therapy management point-of-care device with multiplex and multimodal sensorCardioCap is a handheld POC device that uses a finger-prick blood sample to simultaneously assess heart failure severity through four biomarkers, aiming to reduce re-hospitalization and mortality rates by 30%. | EIC Accelerator | € 2.499.999 | 2025 | Details |
Acorai Heart Monitor - Non-invasive multi-sensor device for heart failure monitoringThe Acorai Heart Monitor is a non-invasive device using machine learning to estimate cardiac pressure in heart failure patients, aiming to improve treatment outcomes and reduce hospitalizations. | EIC Accelerator | € 2.299.633 | 2023 | Details |
Transcatheter Ventricular Repair Device for treatment of Heart Failure Patients
Cardiac Success aims to develop the V-sling, a transcatheter device to enhance heart function in heart failure patients, through product optimization and pre-clinical testing.
A revolutionary technology platform for providing life-saving treatment for end-stage heart failure patients
reBEAT is an innovative heart support technology that safely assists both sides of the heart, aiming to improve treatment accessibility and cost-effectiveness for end-stage heart failure patients.
Innovative, minimally invasive device to support the natural movement of the heart in heart failure patients
Syntach CS is an innovative implantable device that restores natural heart movement in patients with left ventricular heart failure, enhancing cardiac function through synchronized support.
The first heart failure therapy management point-of-care device with multiplex and multimodal sensor
CardioCap is a handheld POC device that uses a finger-prick blood sample to simultaneously assess heart failure severity through four biomarkers, aiming to reduce re-hospitalization and mortality rates by 30%.
Acorai Heart Monitor - Non-invasive multi-sensor device for heart failure monitoring
The Acorai Heart Monitor is a non-invasive device using machine learning to estimate cardiac pressure in heart failure patients, aiming to improve treatment outcomes and reduce hospitalizations.
Vergelijkbare projecten uit andere regelingen
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
Mechanical design concept for Cardiac Recovery Assist DeviceCardiacBooster ontwikkelt een veilig mechanisch device voor hartondersteuning bij acuut hartfalen, met focus op haalbaarheid en validatie via testen en samenwerking met derden. | Mkb-innovati... | € 20.000 | 2020 | Details |
SPARK - Subcutaneous Pump and Advanced Remote KitHet project ontwikkelt een innovatief hartondersteuningssysteem met een subcutane sensor voor betere behandeling van gevorderd hartfalen. | Mkb-innovati... | € 199.138 | 2023 | Details |
CLOBT: Cardiale Levensreddende Ondersteuning Booster TechnoCardiacBooster heeft een innovatief apparaat ontwikkeld dat het hart van binnenuit ondersteunt, met betere resultaten en minder risico's dan bestaande mechanische ondersteuningssystemen voor cardiogene shockpatiënten. | Mkb-innovati... | € 155.376 | 2020 | Details |
Novel microsensing platform for remote patient monitoringThe FORESEE project aims to advance implantable microstimulators for remote monitoring of chronic heart failure, enhancing patient care and market access for 10.5 million potential users. | EIC Transition | € 2.499.051 | 2023 | Details |
Surgical optogenetic bioprinting of engineered cardiac muscleLIGHTHEART aims to revolutionize heart failure treatment by developing a surgical bioprinting tool that uses optogenetics to create engineered cardiac muscle directly at the patient's heart. | ERC Starting... | € 1.499.705 | 2023 | Details |
Mechanical design concept for Cardiac Recovery Assist Device
CardiacBooster ontwikkelt een veilig mechanisch device voor hartondersteuning bij acuut hartfalen, met focus op haalbaarheid en validatie via testen en samenwerking met derden.
SPARK - Subcutaneous Pump and Advanced Remote Kit
Het project ontwikkelt een innovatief hartondersteuningssysteem met een subcutane sensor voor betere behandeling van gevorderd hartfalen.
CLOBT: Cardiale Levensreddende Ondersteuning Booster Techno
CardiacBooster heeft een innovatief apparaat ontwikkeld dat het hart van binnenuit ondersteunt, met betere resultaten en minder risico's dan bestaande mechanische ondersteuningssystemen voor cardiogene shockpatiënten.
Novel microsensing platform for remote patient monitoring
The FORESEE project aims to advance implantable microstimulators for remote monitoring of chronic heart failure, enhancing patient care and market access for 10.5 million potential users.
Surgical optogenetic bioprinting of engineered cardiac muscle
LIGHTHEART aims to revolutionize heart failure treatment by developing a surgical bioprinting tool that uses optogenetics to create engineered cardiac muscle directly at the patient's heart.